The European Commission has announced that it has approved an agreement that allows European Union (EU) member states to purchase up to 200 million doses of Novavax’s Covid-19 vaccine, once the European Medicines Agency ( EMA) deems it safe and efficient to use.

In a statement on Wednesday, the Commission said that thanks to the deal with the US pharmaceutical company, EU countries will be able to purchase 100 million doses of Novavax vaccine, with the possibility of purchasing an additional 100 million over the course of 2021, 2022 and 2023, reports the Xinhua news agency.

European Commission President Ursula von der Leyen hailed the deal as further strengthening the bloc’s “large vaccine portfolio”.

The EU has already signed contracts with AstraZeneca, Sanofi-GSK, Janssen Pharmaceutica NV, BioNTech-Pfizer, CureVac, Moderna and concluded exploratory talks with Valneva.

The contracts previously concluded have made it possible to secure a portfolio of up to 4.4 billion doses.

Wealthy Western nations have been accused of accumulating far more doses than their citizens need.

The Washington Post previously estimated that the United States has bought coronavirus vaccines three times the amount needed, while many developing countries are still struggling to get a single dose.

The World Health Organization (WHO) on Wednesday called on rich countries to suspend the Covid-19 booster vaccine distribution plan, citing the inequality of vaccines around the world.

“We need an urgent reversal of the majority of vaccines intended for high-income countries, the majority for low-income countries,” WHO Director-General Tedros Adhanom Ghebreyesus said at a briefing.


ksk /

(Only the title and image of this report may have been reworked by Business Standard staff; the rest of the content is automatically generated from a syndicated feed.)

Dear reader,

Business Standard has always strived to provide up-to-date information and commentary on developments that matter to you and have broader political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering has only strengthened our resolve and commitment to these ideals. Even in these difficult times resulting from Covid-19, we remain committed to keeping you informed and updated with credible news, authoritative views and cutting-edge commentary on relevant current issues.
However, we have a demand.

As we fight the economic impact of the pandemic, we need your support even more so that we can continue to provide you with more quality content. Our subscription model has received an encouraging response from many of you who have subscribed to our online content. More subscriptions to our online content can only help us achieve the goals of providing you with even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practice the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital editor


Leave a Reply

Your email address will not be published.